Antiphospholipid antibodies (aPL), namely anticardiolipin antibodies (aCL) and lupus anticoagulant (LAC), have been associated with an increased risk of thrombosis in systemic lupus erythematosus (SLE). We examined additional thrombosis risk factors (aPL profile, SLE-related, and traditional risk factors) and the primary thrombosis prevention in SLE patients with and without aPL.All SLE patients with positive aPL but without previous thrombotic manifestations who were regularly followed up at our department (n = 15) and 15 age- and sex-matched SLE patients with negative aPL were included in this study. The median followup times were 1 year. The demographic, clinical, laboratory, and treatment characteristics and the traditional thrombosis risk factors were recorded.The results of this study showed that thrombotic manifestations were observed in 8 (53.3%) of 15 aPL-positive patients and 2 (13.3%) of 15 aPL-negative patients (P = 0.025).